FDA Clocks Review Time for RYTELO Drug Patent Boost
Published Date: 2/13/2026
Notice
Summary
The FDA has officially set the review period for the drug RYTELO, which helps the company apply for extra patent time to protect their invention. This affects the drug maker and anyone tracking patent extensions, with deadlines to challenge dates or diligence claims by April 14 and August 12, 2026. It’s a key step to keep innovation protected while making sure the process stays fair and on schedule.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
FDA Sets RYTELO Review Period
FDA determined the regulatory review period for the drug RYTELO is 6,967 days in total. That includes 6,610 days in the testing phase and 357 days in the approval phase, and this determination establishes the maximum potential length of a patent extension.
Applicant Requests Specific Extension Durations
The patent applicant (Geron Corporation) has applied for patent term restoration and seeks extensions of 1,464 days, 1,622 days, 1,629 days, or the maximum 5 years for U.S. Patent Nos. 7,494,982; 9,375,485; 9,388,415; 9,388,416; and 9,657,296. The USPTO will apply statutory limitations when calculating the actual extension granted.
Deadlines To Challenge Dates or Diligence
Anyone who believes the published dates are incorrect may ask FDA for a redetermination by April 14, 2026. Any interested person may petition FDA about whether the patent applicant acted with due diligence during the regulatory review period by August 12, 2026, and such petitions must meet the requirements of 21 CFR 60.30.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11589 — Medical Devices; Ear, Nose, and Throat Devices; Classification of the Combined Acoustic and Electrical External Stimulation Device for the Relief of Tinnitus
The FDA has officially placed the combined acoustic and electrical external stimulation device for tinnitus relief into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification is effective June 10, 2026, with the rules applying retroactively from March 6, 2023.
2026-11578 — Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information
The FDA just gave a thumbs-up to adding bemotrizinol as a new active ingredient in sunscreens, letting it be used up to 6% concentration. This means sunscreen makers can now include this ingredient, which is safe and effective, in their products. The change is official as of June 10, 2026, and could lead to better sun protection options without extra costs for consumers.
Previous / Next Documents
Previous: 2026-02902 — John Bender, M.D.; Decision and Order
Dr. John Bender from Fort Collins, Florida, had his DEA registration suspended and is now facing revocation because he filled over 4,200 controlled substance prescriptions without the proper pharmacy licenses. This decision protects public health by shutting down unregistered pharmacies operating at his clinics. The changes take effect immediately, impacting Dr. Bender’s ability to legally handle controlled substances and signaling serious legal and financial consequences.
Next: 2026-02904 — Mountain Ventures, Inc., License No. 04/04-0145; Surrender of License of Small Business Investment Company
Mountain Ventures, Inc. has officially given up its license to operate as a Small Business Investment Company. This means they won’t be making new investments under this program anymore, effective immediately. Small businesses and investors connected to Mountain Ventures should take note of this change as it may affect funding opportunities.